Cover Image
市場調查報告書

全球癌症疫苗市場、臨床試驗的考察

Global Cancer Vaccine Market & Clinical Trial Insight

出版商 KuicK Research 商品編碼 339805
出版日期 內容資訊 英文 750 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症疫苗市場、臨床試驗的考察 Global Cancer Vaccine Market & Clinical Trial Insight
出版日期: 2015年09月18日 內容資訊: 英文 750 Pages
簡介

本報告提供癌症疫苗市場、臨床試驗趨勢的相關調查,全球癌症市場概要,定做的貨癌症疫苗的登場,癌症疫苗遞送的平台,癌症疫苗的機制,各相位/適應症/企業/國家的全球癌症疫苗臨床實驗平台,已上市的癌症疫苗,及癌症疫苗開發、行銷的法律規範等相關分析。

第1章 癌症疫苗的簡介

第2章 癌症疫苗的機制

第3章 癌症疫苗的佐劑療法

第4章 全球癌症疫苗市場概要

  • 現狀
  • 全球癌症疫苗開發平台:各適應症

第5章 定做癌症疫苗的登場

第6章 該國HPV癌症疫苗計劃

第7章 全球癌症疫苗市場動態

第8章 全球癌症疫苗市場未來展望

第9章 膀胱癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第二階段

第10章 血液癌症疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 研究階段∼登記前

第11章 腦瘤的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第12章 乳癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第13章 癌症疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 研究階段∼第二階段

第14章 子宮頸癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第二階段∼第三階段

第15章 大腸癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第二階段

第16章 頭頸椎癌症疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第一/二階段

第17章 肝癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第一階段∼第二階段

第18章 肺癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第19章 食道癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第三階段

第20章 卵巢癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第21章 胰臟癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 研究階段∼登記前

第22章 前列腺癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第23章 腎臟癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第24章 肉瘤疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 第二階段

第25章 皮膚癌疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第三階段

第26章 固態腫瘤疫苗的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第27章 多發性癌症的臨床實驗平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第28章 已上市癌症疫苗的臨床實驗平台:各企業、各適應症

  • 膀胱癌
  • 子宮頸癌
  • 肺癌
  • 胰臟癌
  • 前列腺癌
  • 皮膚癌
  • 多發性癌症

第29章 中止、停止的癌症疫苗產品的臨床實驗平台考察

  • 沒有臨床報告
  • 臨床中止
  • 臨床停止

第30章 對癌症疫苗開發、行銷的FDA法律規範

  • 初期、後期階段的臨床試驗雙方的考察
  • 初期階段的臨床試驗的考察
  • 後期階段的臨床試驗的考察

第31章 競爭情形:產業概要 & 產品平台

  • Advaxis
  • AVAX Technologies
  • Celldex Therapeutics
  • Dendreon Corporation
  • Galena Biopharma
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • KAEL-GemVax
  • Liponova
  • MedImmune
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Recombio
  • Roche
  • Sanofi
  • Seattle Genetics
  • Valeant Pharmaceuticals

圖表一覽

目錄

The concept of vaccines dates back to1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.

Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

  • Global Cancer Market Overview
  • Emergence of Personalized Cancer Vaccines
  • Platforms for Cancer Vaccines Delivery
  • Mechanism of Cancer Vaccines
  • Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
  • Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
  • Marketed Cancer Vaccines: 15 Vaccines
  • Regulatory Framework for Cancer Vaccines Development & Marketing

Table of Contents

1. Introduction to Cancer Vaacines

2. Mechanism of Cancer Vaccines

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Therapy for Cancer Vaccines

4. Global Cancer Vaccines Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Global Cancer Vaccine Drug Pipeline by Indication

5. Emergence of Personalized Cancer Vaccines

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics

  • 7.1. Favorable Market Parameters
    • 7.1.1. Pottential Demand for Cancer Vaccines
    • 7.1.2. Public Cancer Vaccination Program
    • 7.1.3. Advancements in Development Technology
    • 7.1.4. Personalized Cancer Vaccines
    • 7.1.5. Myriad of Demographs for Cancer Vaccine Development
  • 7.2. Commercialization Challenges

8. Global Cancer Vaccine Market Future Outlook

9. Bladder Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 9.1. Phase-II

10. Blood Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 10.1. Research till Preregistration

11. Brain Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 11.1. Preclinical Till Phase-III

12. Breast Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 12.1. Preclinical till Phase-III

13. Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 13.1. Research till Phase-II

14. Cervical Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 14.1. Phase-II

15. Colorectal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 15.1. Preclinical till Preregistration

16. Head and Neck Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 16.1. Preclinical till Phase-I/II

17. Liver Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 17.1. Phase-I till Phase-II

18. Lung Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 18.1. Preclinical till Phase-III

19. Oesophageal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 19.1. Phase-III

20. Ovarian Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 20.1. Preclinical till Phase-III

21. Pancreatic Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 21.1. Reseach till Phase-III

22. Prostate Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 22.1. Preclinical till Phase-III

23. Renal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 23.1. Phase-I till Phase-III

24. Sarcoma Vaccine Clinical Pipeline Insight by Company & Phase

  • 24.1. Phase-II

25. Skin Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 25.1. Preclinical till Phase-III

26. Solid Tumours Vaccine Clinical Pipeline Insight by Company & Phase

  • 26.1. Preclinical till Phase-II

27. Multiple Cancer Vaccine Clinical Pipeline Insight by Company & Phase

  • 27.1. Preclinical till Phase-III

28. Marketed Cancer Vaccine Clinical Insight by Company & Indication

  • 28.1. Bladder Cancer
    • 28.1.1. BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)
    • 28.1.2. Bladder Cancer Vaccine (PACIS®)
    • 28.1.3. Bladder Cancer Vaccine - Organon Teknika
  • 28.2. Cervical Cancer
    • 28.2.1. Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
  • 28.3. Lung Cancer
    • 28.3.1. BV NSCLC 001
    • 28.3.2. Cadi 05(Immuvac® & Mycidac-C™)
    • 28.3.3. Racotumomab (Vaxira®)
  • 28.4. Pancreatic Cancer
    • 28.4.1. Tertomotide (LucaVax)
  • 28.5. Prostate Cancer
    • 28.5.1. Sipuleucel-T (Provenge®)
  • 28.6. Renal Cancer
    • 28.6.1. Renal Cancer Vaccine (Reniale®)
    • 28.6.2. Vitespen (Oncophage®)
  • 28.7. Skin Cancer
    • 28.7.1. Melanoma Vaccine (MVax®)
    • 28.7.2. Melanoma Vaccine (Melacine®)
  • 28.8. Multiple Cancer
    • 28.8.1. Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)
    • 28.8.2. Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. Discontinued & Suspended Cancer Vaccine Drug Clinical Pipeline Insight

  • 29.1. No Development Reported
  • 29.2. Discontinued
  • 29.3. Suspended

30. FDA Regulatory Framework for Cancer Vaccines Development & Marketing

  • 30.1. Considerations for both Early and Late Phase Clinical Trials
    • 30.1.1. Patient Population
    • 30.1.2. Monitoring the Immune Response
    • 30.1.3. Biomarkers as Evidence Of Efficacy
    • 30.1.4. Adjuvants Used To Stimulate Immune Response
    • 30.1.5. Multi-Antigen Vaccines
    • 30.1.6. Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
    • 30.1.7. Concomitant and Subsequent Therapies
  • 30.2. Considerations for Early Phase Clinical Trials
    • 30.2.1. Starting Dose and Dosing Schedule
    • 30.2.2. Booster and Maintenance Therapy
    • 30.2.3. Dose Escalation
    • 30.2.4. Single-Arm versus Randomized Phase 2 Trials In Early Development
  • 30.3. Considerations for Late Phase Clinical Trials
    • 30.3.1. Safety Profile from Early Phase Clinical Trials
    • 30.3.2. Endpoints
    • 30.3.3. Statistical Issues
    • 30.3.4. Control Issues
    • 30.3.5. Delayed Vaccine Effect
    • 30.3.6. Autologous Vaccine Trials
    • 30.3.7. Accelerated Approval Regulations

31. Competitive Landscape: Business Overview & Product Pipeline

  • 31.1. Advaxis
  • 31.2. AVAX Technologies
  • 31.3. Celldex Therapeutics
  • 31.4. Dendreon Corporation
  • 31.5. Galena Biopharma
  • 31.6. GlaxoSmithKline
  • 31.7. ImmunoCellular Therapeutics
  • 31.8. ImmunoGen
  • 31.9. Inovio Pharmaceuticals
  • 31.10. KAEL-GemVax
  • 31.11. Liponova
  • 31.12. MedImmune
  • 31.13. Merck
  • 31.14. NeoStem Oncology
  • 31.15. NewLink Genetics
  • 31.16. Northwest Biotherapeutics
  • 31.17. Novartis
  • 31.18. Peregrine Pharmaceuticals
  • 31.19. Recombio
  • 31.20. Roche
  • 31.21. Sanofi
  • 31.22. Seattle Genetics
  • 31.23. Valeant Pharmaceuticals

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
  • Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
  • Figure 4-3: Examples of Commercially Available Cancer Vaccines
  • Figure 4-4: Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-5: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-6: Bladder Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-7: Bladder Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-8: Blood Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-9: Blood Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-10: Brain Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-11: Brain Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-12: Breast Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-13: Breast Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-14: Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-15: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-16: Cervical Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-17: Cervical Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-18: Colorecta Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-19: Colorecta Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-20: Head & Neck Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-21: Head & Neck Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-22: Liver Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-23: Liver Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-24: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-25: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-26: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-27: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-28: Pancreatic Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-29: Pancreatic Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-30: Prostate Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-31: Prostate Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-32: Renal Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-33: Renal Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-34: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-35: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-36: Solid Tumour Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-37: Solid Tumour Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-38: Multiple Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-39: Multiple Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-40: No Development Reported Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-41: No Development Reported Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-42: Discontinued Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-43: Discontinued Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 4-44: Suspended Cancer Vaccine Drug Pipeline by Phase (%), 2015
  • Figure 4-45: Suspended Cancer Vaccine Drug Pipeline by Phase (Number), 2015
  • Figure 5-1: Overview of Personalized Cancer Vaccines Development
  • Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
  • Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
  • Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines
  • Figure 31-1: Advaxis Clinical Pipeline
  • Figure 31-2: Celldex Therapeutics Clinical Pipeline
  • Figure 31-3: Galena Biopharma Clinical Pipeline
  • Figure 31-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 31-5: ImmunoGen Clinical Pipeline
  • Figure 31-6: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 31-7: KAEL-Gemvax Clinical Pipeline
  • Figure 31-8: NewLink Genetics Corporation Clinical Pipeline
  • Figure 31-9: Northwest Biotherapeutics Clinical Pipeline
  • Figure 31-10: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 31-11: Seattle Genetics Clinical Pipeline

List of Tables

  • Table 5-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development
Back to Top